Cadence Pharmaceuticals, (FRA:QEW) Total Assets : €66.29 Mil (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Total Assets?

Cadence Pharmaceuticals,'s Total Assets for the quarter that ended in Dec. 2013 was €66.29 Mil.

Total Assets is connected with ROA %. Cadence Pharmaceuticals,'s annualized ROA % for the quarter that ended in Dec. 2013 was -18.62%. Total Assets is also linked to Revenue through Asset Turnover. Cadence Pharmaceuticals,'s Asset Turnover for the quarter that ended in Dec. 2013 was 0.40.

Cadence Pharmaceuticals, Total Assets Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Total Assets Chart

Cadence Pharmaceuticals, Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Total Assets

Get a 7-Day Free Trial

63.50

123.82

124.39

74.43

66.29

Cadence Pharmaceuticals, Quarterly Data
	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13
Total Assets	Get a 7-Day Free Trial															74.43	73.85	67.88	62.85	66.29

Cadence Pharmaceuticals, Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cadence Pharmaceuticals,'s Total Assets for the fiscal year that ended in Dec. 2013 is calculated as

Total Assets	=	Total Equity (A: Dec. 2013 )	+	Total Liabilities (A: Dec. 2013 )
	=	25.461	+	40.825
	=	66.29

Cadence Pharmaceuticals,'s Total Assets for the quarter that ended in Dec. 2013 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2013 )	+	Total Liabilities (Q: Dec. 2013 )
	=	25.461	+	40.825
	=	66.29

Cadence Pharmaceuticals, (FRA:QEW) Total Assets Explanation

Total Assets is connected with ROA %.

Cadence Pharmaceuticals,'s annualized ROA % for the quarter that ended in Dec. 2013 is

ROA %	=	Net Income (Q: Dec. 2013 )	/	( (Total Assets (Q: Sep. 2013 )	+	Total Assets (Q: Dec. 2013 ))	/ count )
	=	-12.024	/	( (62.85	+	66.286)	/ 2 )
	=	-12.024	/	64.568
	=	-18.62 %

Note: The Net Income data used here is four times the quarterly (Dec. 2013) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cadence Pharmaceuticals,'s Asset Turnover for the quarter that ended in Dec. 2013 is

	Asset Turnover
=	Revenue (Q: Dec. 2013 )	/	( (Total Assets (Q: Sep. 2013 )	+	Total Assets (Q: Dec. 2013 ))	/ count )
=	25.778	/	( (62.85	+	66.286)	/ 2 )
=	25.778	/	64.568
=	0.40

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cadence Pharmaceuticals, Total Assets Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cadence Pharmaceuticals, (FRA:QEW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cadencepharm.com

Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines